WO2005082866A3 - Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists - Google Patents

Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists Download PDF

Info

Publication number
WO2005082866A3
WO2005082866A3 PCT/IB2005/000313 IB2005000313W WO2005082866A3 WO 2005082866 A3 WO2005082866 A3 WO 2005082866A3 IB 2005000313 W IB2005000313 W IB 2005000313W WO 2005082866 A3 WO2005082866 A3 WO 2005082866A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
oxytocin antagonists
triazole derivatives
inhibitors
oxytocin
Prior art date
Application number
PCT/IB2005/000313
Other languages
French (fr)
Other versions
WO2005082866A2 (en
Inventor
Alan Daniel Brown
Andrew Anthony Calabrese
David Ellis
Christopher Ronald Smith
Original Assignee
Pfizer Ltd
Pfizer
Alan Daniel Brown
Andrew Anthony Calabrese
David Ellis
Christopher Ronald Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403861A external-priority patent/GB0403861D0/en
Application filed by Pfizer Ltd, Pfizer, Alan Daniel Brown, Andrew Anthony Calabrese, David Ellis, Christopher Ronald Smith filed Critical Pfizer Ltd
Publication of WO2005082866A2 publication Critical patent/WO2005082866A2/en
Publication of WO2005082866A3 publication Critical patent/WO2005082866A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).
PCT/IB2005/000313 2004-02-20 2005-02-07 Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists WO2005082866A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0403861.8 2004-02-20
GB0403861A GB0403861D0 (en) 2004-02-20 2004-02-20 New substituted triazoles for use as novel pharmaceuticals
US57453104P 2004-05-26 2004-05-26
US60/574,531 2004-05-26

Publications (2)

Publication Number Publication Date
WO2005082866A2 WO2005082866A2 (en) 2005-09-09
WO2005082866A3 true WO2005082866A3 (en) 2006-04-13

Family

ID=34913650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000313 WO2005082866A2 (en) 2004-02-20 2005-02-07 Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists

Country Status (1)

Country Link
WO (1) WO2005082866A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884071A (en) * 2016-12-21 2018-11-23 江苏恒瑞医药股份有限公司 Condensed ring radical azelidinyl triazole derivative, preparation method and its application in medicine

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
EP1917257A1 (en) * 2005-08-10 2008-05-07 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
EP1928846B1 (en) 2005-08-18 2014-06-04 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2118077B1 (en) 2007-02-08 2014-12-24 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2012007500A2 (en) 2010-07-15 2012-01-19 Bayer Cropscience Ag New heterocyclic compounds as pesticides
JO3705B1 (en) 2014-11-26 2021-01-31 Bayer Pharma AG Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments
EP3195865A1 (en) 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
TW201701879A (en) 2015-04-30 2017-01-16 拜耳製藥公司 Combinations of IRAK4 inhibitors
EP3423446B1 (en) 2016-03-03 2020-09-16 Bayer Pharma Aktiengesellschaft New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2017207340A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Novel substituted benzimidazole, methods for the production thereof, pharmaceutical preparations containing same, and use thereof to produce medicaments
WO2017207385A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted 3-methylindazoles, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
UA124237C2 (en) 2016-06-01 2021-08-11 Байєр Енімал Хелс Гмбх Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
SG11201810769QA (en) 2016-06-01 2018-12-28 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
WO2018060174A1 (en) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituted benzimidazoles, pharmaceutical preparations containing same, and use of same to produce drugs
AU2017389819B2 (en) 2016-12-28 2021-05-27 Jiangsu Hengrui Medicine Co., Ltd. Azabicyclo-substituted triazole derivative, preparation method thereof, and application of same in medicine
WO2020157201A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Oxadiazinone compounds for the treatment of hyperproliferative diseases
CN113004250B (en) * 2019-12-19 2022-07-26 上海森辉医药有限公司 Process for preparing substituted triazole derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063363A (en) * 1998-08-12 2000-02-29 Yamanouchi Pharmaceut Co Ltd New triazole derivative
WO2001058880A1 (en) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Novel triazole derivatives
WO2003053437A1 (en) * 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Triazoles as oxytocin antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063363A (en) * 1998-08-12 2000-02-29 Yamanouchi Pharmaceut Co Ltd New triazole derivative
WO2001058880A1 (en) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Novel triazole derivatives
WO2003053437A1 (en) * 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Triazoles as oxytocin antagonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884071A (en) * 2016-12-21 2018-11-23 江苏恒瑞医药股份有限公司 Condensed ring radical azelidinyl triazole derivative, preparation method and its application in medicine
CN108884071B (en) * 2016-12-21 2021-05-14 江苏恒瑞医药股份有限公司 Condensed ring based azetidinyl triazole derivative, preparation method and application thereof in medicine

Also Published As

Publication number Publication date
WO2005082866A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
WO2005082866A3 (en) Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
WO2006100588A8 (en) Substituted triazole derivatives as oxytocin antagonists
TW200637847A (en) Substituted triazole derivatives as oxytocin antagonists
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
WO2006116733A3 (en) Protein kinase inhibitors
BRPI0511979A (en) substituted triazole derivatives as oxytocin antagonists, pharmaceutical composition comprising said derivatives and use thereof
WO2005037825A3 (en) Protein kinase inhibitors
WO2006048330A8 (en) 11βετα-hsd1 inhibitors
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
ZA200609634B (en) Quinazolinone derivatives useful as vanilloid antagonists
WO2004087699A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2004087698A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2004112719A3 (en) Chemical compounds
WO2007050587A3 (en) Therapeutic compositions and methods
CO5631443A2 (en) DERIVATIVES OF 7-ARIL-3,9-DIAZABICICLO (3.3.1) NON-6-ENO AND ITS USE AS RHENINE INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES
TW200626593A (en) Novel compounds
TW200745122A (en) New compounds I
WO2004026836A8 (en) 1-pyridin-4-yl-urea derivatives
GB0513886D0 (en) Novel compounds
TW200621773A (en) Bicyclononene derivatives
WO2009019176A3 (en) Fungicidal mixtures
BRPI0414663A (en) substituted triazole derivatives as oxytocin antagonists
WO2005030209A8 (en) Pyridine derivatives and use thereof as urotensin ii antagonists
TW200628153A (en) Novel compounds
TW200628468A (en) Bicyclononene derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase